OtherGastrointestinal, Hepatic, Pulmonary, and Renal
Pharmacological Properties of 552-02, a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung Disease
Andrew J. Hirsh, Jim Zang, Andra Zamurs, Jacquelyn Fleegle, William R. Thelin, Raymond A. Caldwell, Juan Sabater, William M. Abraham, Mark Donowitz, Boyoung Cha, Kevin B. Johnson, J. St. George, M. Ross Johnson and Richard C. Boucher
Journal of Pharmacology and Experimental Therapeutics January 24, 2008, DOI: https://doi.org/10.1124/jpet.107.130443
Andrew J. Hirsh
Jim Zang
Andra Zamurs
Jacquelyn Fleegle
William R. Thelin
Raymond A. Caldwell
Juan Sabater
William M. Abraham
Mark Donowitz
Boyoung Cha
Kevin B. Johnson
J. St. George
M. Ross Johnson
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
OtherGastrointestinal, Hepatic, Pulmonary, and Renal
Pharmacological Properties of 552-02, a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung Disease
Andrew J. Hirsh, Jim Zang, Andra Zamurs, Jacquelyn Fleegle, William R. Thelin, Raymond A. Caldwell, Juan Sabater, William M. Abraham, Mark Donowitz, Boyoung Cha, Kevin B. Johnson, J. St. George, M. Ross Johnson and Richard C. Boucher
Journal of Pharmacology and Experimental Therapeutics January 24, 2008, DOI: https://doi.org/10.1124/jpet.107.130443
OtherGastrointestinal, Hepatic, Pulmonary, and Renal
Pharmacological Properties of 552-02, a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung Disease
Andrew J. Hirsh, Jim Zang, Andra Zamurs, Jacquelyn Fleegle, William R. Thelin, Raymond A. Caldwell, Juan Sabater, William M. Abraham, Mark Donowitz, Boyoung Cha, Kevin B. Johnson, J. St. George, M. Ross Johnson and Richard C. Boucher
Journal of Pharmacology and Experimental Therapeutics January 24, 2008, DOI: https://doi.org/10.1124/jpet.107.130443
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement